A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

ClinicalTrials.gov ID: NCT06373146

Public ClinicalTrials.gov record NCT06373146. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

Study identification

NCT ID: NCT06373146
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 392 participants

Conditions and interventions

Conditions

Obesity

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 24, 2024 (Actual)
Primary completion: Dec 15, 2025 (Actual)
Completion: Apr 2, 2026 (Actual)
Last update posted: May 6, 2026

2024 – 2026

United States locations

U.S. sites: 17
U.S. states: 8
U.S. cities: 17

Facility	City	State	ZIP	Site status
Velocity Clinical Research, Gardena	Gardena	California	90247	—
Irvine Clinical Research	Irvine	California	92614	—
Velocity Clinical Research, Los Angeles	Los Angeles	California	90017	—
Velocity Clinical Research, North Hollywood	North Hollywood	California	91606	—
Velocity Clinical Research, Santa Ana	Santa Ana	California	92704	—
Velocity Clinical Research, Panorama City	Van Nuys	California	91405	—
Diablo Clinical Research, Inc.	Walnut Creek	California	94598	—
Solaris Clinical Research	Meridian	Idaho	83646	—
Tandem Clinical Research	Marrero	Louisiana	70072	—
Velocity Clinical Research - New Orleans	New Orleans	Louisiana	70119	—
Hassman Research Institute Marlton Site	Marlton	New Jersey	08053	—
Lillestol Research	Fargo	North Dakota	58104	—
CTI Clinical Research Center	Cincinnati	Ohio	45212	—
South Texas Clinical Research	Corpus Christi	Texas	78404	—
Velocity Clinical Research, Dallas	Dallas	Texas	75230	—
Juno Research	Houston	Texas	77040	—
Northwest Clinical Research Center	Bellevue	Washington	98007	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06373146, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 6, 2026 · Synced Oct 19, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06373146 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →